Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary CNS lymphoma.

E A Maher1, H A Fine

  • 1Center for Neuro-Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Seminars in Oncology
|June 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth.

Acta neuropathologica communications·2024
Same author

An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.

The pharmacogenomics journal·2014
Same author

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

Neurology·2011
Same author

Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma.

Carcinogenesis·2007
Same author

Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphate-sensitive potassium channels.

The Journal of clinical endocrinology and metabolism·2005
Same author

Season of birth and risk of brain tumors in adults.

Neurology·2004
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Primary CNS lymphoma (PCNSL) treatment is evolving. While radiation offers initial remission, chemotherapy shows promise for prolonged survival, though optimal strategies require further definition.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Clinical Oncology

Background:

  • Primary CNS lymphoma (PCNSL) incidence is rising in immunocompetent and immunocompromised individuals.
  • Historically, radiation therapy was standard, achieving remissions but often followed by relapse and short survival (<2 years).

Purpose of the Study:

  • To review current management of PCNSL.
  • To address key questions regarding optimal chemotherapy regimens and the role of radiation therapy.
  • To provide recommendations for future treatment strategies.

Main Methods:

  • Literature review of primary CNS lymphoma management.
  • Analysis of historical and current treatment outcomes.
  • Discussion of unresolved questions in PCNSL therapy.

Related Experiment Videos

Main Results:

  • Chemotherapy is altering the natural history of PCNSL, with evidence of significantly prolonged survival in certain patient groups.
  • Optimal chemotherapy agents, doses, schedules, and routes of administration remain undefined.
  • The necessity and timing of radiation therapy in conjunction with chemotherapy are not yet established.

Conclusions:

  • Current PCNSL management requires further optimization.
  • Further research is needed to define the best chemotherapy regimens and the role of radiation therapy.
  • Recommendations are proposed for designing future clinical trials and treatment protocols for PCNSL.